Conclusions
The First International Symposium on Myelodysplastic Syndromes gave a comprehensive overview of classification, pathology, and diagnosis of MDS. Further clues to pathogenesis lie in understanding the events at a molecular level. Haematopoietic growth factor therapy opens a new and exciting phase in the treatment of haematological malignancies including myelodysplastic syndromes. Randomized controlled multicenter trials are necessary to define the therapeutic value of low-dose AraC, intensive chemotherapy and treatment with differentiating agents such as 13-cis-retinoic acid. It is hoped within the next 3 years several of the questions raised in this meeting will be answered. The next meeting will be held in 1991 in the United Kingdom.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zwierzina, H., Mufti, G.J. & Schmalzl, F. First international symposium on myelodysplastic syndrome. J Cancer Res Clin Oncol 115, 300–307 (1989). https://doi.org/10.1007/BF00391707
Issue Date:
DOI: https://doi.org/10.1007/BF00391707